| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Flowering plant uses ginger root for help with nausea, weight loss, arthritis, diabetes. Anti-inflammatory and antioxidant. Gingerol is a phenolic phytochemical compound found in fresh ginger that activates heat receptors on the tongue. It is normally found as a pungent yellow oil in the ginger rhizome. Ginger contains multiple bioactive compounds including 6-gingerol, 8-gingerol, 10-gingerol, 6-shogaol, paradols, and zingerone. In cancer-focused literature, the majority of mechanistic work centers on 6-gingerol and 6-shogaol. Mechanistic themes (preclinical): -Anti-inflammatory (NF-κB↓, COX-2↓) -Survival pathway modulation (PI3K/AKT↓, STAT3↓ reported) -MAPK modulation (ERK/JNK/p38 context-dependent) -ROS modulation (antioxidant in normal cells; pro-oxidant at higher doses in tumor models) -Cell-cycle arrest (G1 or G2/M reported) -Apoptosis induction (mitochondrial pathway) -Anti-angiogenic and anti-metastatic signaling (VEGF↓, MMPs↓ reported) Bioavailability note: -Gingerols are rapidly metabolized (glucuronidation/sulfation) -Plasma levels after dietary intake are far below many in-vitro micromolar doses -6-Shogaol is generally more potent than 6-gingerol in cell systems Ginger / 6-Gingerol / 6-Shogaol — Ginger is the rhizome of Zingiber officinale Roscoe and a botanical mixture containing pungent phenolic compounds, principally 6-gingerol in fresh ginger and increased proportions of 6-shogaol after drying or heating. It is formally classified as a medicinal food and botanical product; 6-gingerol and 6-shogaol are phenolic vanilloids, with 6-shogaol additionally functioning as an electrophilic Michael acceptor. Standard abbreviations include ginger, 6-G, 6-GIN, 6-SG and 6-SHO. Other constituents include 8-gingerol, 10-gingerol, paradols and zingerone. The anticancer evidence is predominantly preclinical and should not be equated with the established clinical use of ginger for nausea. Primary mechanisms (ranked):
Bioavailability / PK relevance: Gingerols and shogaols are absorbed orally but undergo extensive first-pass glucuronidation and sulfation. Circulating exposure consists predominantly of conjugated metabolites rather than free parent compounds. 6-Shogaol is generally more reactive and more potent than 6-gingerol in cell models, but it is chemically and metabolically unstable. Glucuronidation markedly reduces its cytotoxic and NRF2-modulating activity. Botanical preparations vary substantially according to cultivar, extraction method, storage, drying and heating. In-vitro vs systemic exposure relevance: Most anticancer experiments use approximately 10–100 µM parent 6-gingerol or 6-shogaol. These concentrations generally exceed sustained free systemic exposure achievable through ordinary dietary ginger or conventional oral supplements. Colon and gastrointestinal tissues may receive greater local exposure to parent compounds and metabolites than distant tumors. The observed selectivity between malignant and normal cells remains model-dependent rather than clinically established. Clinical evidence status: Anticancer treatment evidence remains preclinical, consisting mainly of cell studies and animal xenograft models. Small randomized human studies have examined colorectal mucosal biomarkers, inflammatory eicosanoids and chemotherapy-induced nausea rather than tumor regression or survival. Results for chemotherapy-induced nausea are mixed, although some trials report improved quality of life or reduced acute symptoms when ginger is used adjunctively with standard antiemetics. Ginger is not an approved anticancer therapy, and purified 6-gingerol or 6-shogaol has not demonstrated clinical anticancer efficacy. Safety / interaction constraints: Food-level ginger is generally well tolerated; concentrated supplements can cause gastrointestinal discomfort or heartburn. Platelet inhibition and clinically relevant bleeding interactions remain incompletely defined, but caution is appropriate with warfarin, direct oral anticoagulants, antiplatelet drugs, bleeding disorders and surgery. Product standardization is important because dried or thermally processed ginger may contain substantially more 6-shogaol than fresh ginger. Gingerol and Shogaol Mechanistic Profile
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| Also known as CP32. Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death. As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression. Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy. Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent. On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer. Procaspase-3 is a apoptotic marker protein. Prognostic significance: • High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers. • Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers. |
| 7138- | GI, | 6-Shogaol exerts anti-proliferative and pro-apoptotic effects through the modulation of STAT3 and MAPKs signaling pathways |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Lung, | A549 |
| 7136- | GI, | [6]-shogaol inhibits growth and induces apoptosis of non-small cell lung cancer cells by directly regulating Akt1/2 |
| - | vitro+vivo, | NSCLC, | H1650 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:88 Target#:42 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid